Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731886 · ClinicalTrials.gov registry record · Phase 4
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
A Phase 4 study of Multiple Myeloma, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01731886: Completed Phase 4 study of Multiple Myeloma, sponsored by Columbia University.
NCT01731886 is a Phase 4 study of Multiple Myeloma that has completed, run by Columbia University. The registered enrollment target is 60 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01731886, a Phase 4 study of Multiple Myeloma, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
Primary Outcome
The primary objective of this study is to determine the complete response rate of lenalidomide and low-dose dexamethasone versus that of lenalidomide and low-dose dexamethasone followed by autologous peripheral blood stem cell transplant in patients with newly diagnosed multiple myeloma (will include unconfirmed complete response (CR), CR and stringent complete response (sCR)).
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Lenalidomide
- PROCEDURE Autologous peripheral blood stem cell transplant
- PROCEDURE Stem cell collection
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-04-11 |
| Phase | Phase 4 |
What the finished NCT01731886 record still lists
NCT01731886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT01731886 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01731886 about?
NCT01731886 is a clinical study titled "Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma". The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respon...
What is the current status of trial NCT01731886?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2012-09. Estimated completion is 2017-04-11.
What conditions does trial NCT01731886 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01731886?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Autologous peripheral blood stem cell transplant (PROCEDURE), Stem cell collection (PROCEDURE).
Who is sponsoring clinical trial NCT01731886?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01731886 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01731886's enrollment target sits among peer trials
60 228th of 438 higher than 205 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia